Moderna finalizes decade-long mRNA alliance with U.K.

Moderna announced Thursday that it has finalized a 10-year partnership with the U.K. government to invest in mRNA technology research and development.

As part of the agreement, which was first announced in June, Moderna stated that it will build a state-of-the-art mRNA manufacturing facility that is projected to produce up to 250 million vaccines per year. Construction on the building is expected to start in early 2023 and produce the first mRNA vaccine in the U.K. in 2025.